Summary
DexCom, Inc. (DXCM) has entered into a Warrant Termination Agreement with Bank of America, N.A. (BofA) on February 13, 2024, to terminate outstanding warrants related to its 0.75% Convertible Senior Notes due 2023. These warrants were originally issued in connection with the convertible notes and associated hedge and warrant transactions with BofA and JPMorgan Chase Bank (JPM). The termination agreement will resolve approximately 10.3 million shares of common stock warrants held by BofA. In exchange for the warrant termination, DexCom will issue shares of its common stock to BofA. The number of shares will be determined by the daily volume-weighted average price of DexCom's common stock over a specified averaging period expected to conclude in the first quarter of 2024. This transaction is being conducted under an exemption from registration, implying it is not being offered to the public and is intended to simplify the company's capital structure and remove potential future dilution from these specific warrants.
Key Highlights
- 1DexCom terminates a material definitive agreement concerning outstanding warrants with Bank of America.
- 2The agreement specifically addresses warrants originally tied to the 0.75% Convertible Senior Notes due 2023.
- 3Approximately 10.3 million shares of DexCom's common stock, subject to anti-dilution adjustments, are involved in this termination.
- 4DexCom will issue shares of its common stock to Bank of America as consideration for the warrant termination.
- 5The number of shares to be issued will be based on a volume-weighted average price (VWAP) during a defined averaging period.
- 6The averaging period is expected to conclude in the first quarter of 2024.
- 7The issuance of shares is being made under an exemption from registration (Section 4(a)(2) of the Securities Act of 1933), indicating a private transaction.